No price history available.
Key financial summary
Financials in GBP| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | £m | 37 | 41 | 41 | 38 | 38 | 48 | N/A | N/A |
| Operating profit | £m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | £m | 3 | 4 | 0 | -6 | -15 | -1 | N/A | N/A |
| EPS reported | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | £m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | £m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | £m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in GBP| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Inspiration Healthcare Group plc (IHC.L) is a global provider of advanced medical technology, catering to critical care, operating theatre, and home healthcare applications worldwide. The company offers a comprehensive range of products, with a strong focus on neonatal intensive care. This includes air/oxygen blenders; the Tecotherm Neo, a sophisticated servo-controlled device that precisely manages infant body temperature through continuous cooling and warming, making minute adjustments every two seconds to ensure stability; LifeStart, a bedside unit for neonatal resuscitation; and Inspire rPAP, a non-invasive, two-piece system crucial for the initial stabilization and resuscitation of infants. Beyond neonatal care, Inspiration Healthcare also supplies adult intensive care solutions, such as AlphaCore5, a patient warming system designed to prevent inadvertent hypothermia. For neonates, they provide CosyTherm2, another dedicated patient warming system for precise temperature management. Their offerings also encompass various respiratory disposables and thermoregulating products specifically for babies. In addition to its proprietary innovations, the company distributes third-party medical products, including infusion therapy items vital for parenteral feeding and chemotherapy. Inspiration Healthcare Group further enhances its services by offering technology support and supplying spare parts. Established in 1998, Inspiration Healthcare Group plc maintains its headquarters in Crawley, United Kingdom.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Inspiration Healthcare Group plc (IHC.L)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Inspiration Healthcare Group plc (IHC.L) is a global provider of advanced medical technology, catering to critical care, operating theatre, and home healthcare applications worldwide. The company offers a comprehensive range of products, with a strong focus on neonatal intensive care. This includes air/oxygen blenders; the Tecotherm Neo, a sophisticated servo-controlled device that precisely manages infant body temperature through continuous cooling and warming, making minute adjustments every two seconds to ensure stability; LifeStart, a bedside unit for neonatal resuscitation; and Inspire rPAP, a non-invasive, two-piece system crucial for the initial stabilization and resuscitation of infants. Beyond neonatal care, Inspiration Healthcare also supplies adult intensive care solutions, such as AlphaCore5, a patient warming system designed to prevent inadvertent hypothermia. For neonates, they provide CosyTherm2, another dedicated patient warming system for precise temperature management. Their offerings also encompass various respiratory disposables and thermoregulating products specifically for babies. In addition to its proprietary innovations, the company distributes third-party medical products, including infusion therapy items vital for parenteral feeding and chemotherapy. Inspiration Healthcare Group further enhances its services by offering technology support and supplying spare parts. Established in 1998, Inspiration Healthcare Group plc maintains its headquarters in Crawley, United Kingdom.
